As global markets navigate the complexities of interest rate expectations and economic shifts, Asian markets continue to capture investor attention with their unique opportunities. Penny stocks, often associated with smaller or newer companies, remain a relevant area of interest for investors seeking affordability and growth potential. This article explores three promising Asian penny stocks that stand out for their financial strength and potential upside in today's market landscape.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| Food Moments (SET:FM) | THB3.94 | THB3.89B | ✅ 4 ⚠️ 0 View Analysis > |
| JBM (Healthcare) (SEHK:2161) | HK$3.03 | HK$2.47B | ✅ 3 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.59 | HK$983.45M | ✅ 4 ⚠️ 1 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.38 | HK$1.97B | ✅ 4 ⚠️ 1 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD0.91 | SGD368.81M | ✅ 4 ⚠️ 1 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.82 | THB2.89B | ✅ 3 ⚠️ 3 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.20 | SGD12.59B | ✅ 5 ⚠️ 1 View Analysis > |
| Ekarat Engineering (SET:AKR) | THB0.97 | THB1.43B | ✅ 2 ⚠️ 2 View Analysis > |
| Livestock Improvement (NZSE:LIC) | NZ$0.98 | NZ$139.5M | ✅ 2 ⚠️ 5 View Analysis > |
| Rojana Industrial Park (SET:ROJNA) | THB4.96 | THB10.02B | ✅ 3 ⚠️ 3 View Analysis > |
Click here to see the full list of 977 stocks from our Asian Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Logory Logistics Technology (SEHK:2482)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Logory Logistics Technology Co., Ltd. offers road freight transportation services and solutions to various stakeholders in the logistics industry in China, with a market cap of HK$1.32 billion.
Operations: The company generates CN¥7.31 billion in revenue from its digital freight businesses and related services.
Market Cap: HK$1.32B
Logory Logistics Technology has demonstrated robust earnings growth, with a 161.7% increase over the past year, significantly outpacing the logistics industry average. Despite its low return on equity of 6.7%, the company maintains high-quality earnings and improved net profit margins from 0.3% to 0.7%. Its financial health is supported by short-term assets exceeding liabilities and more cash than total debt, with interest well covered by EBIT at 11.4 times coverage. Trading at nearly 70% below estimated fair value, Logory's volatility remains high but stable compared to other Hong Kong stocks.
- Take a closer look at Logory Logistics Technology's potential here in our financial health report.
- Evaluate Logory Logistics Technology's historical performance by accessing our past performance report.
IGG (SEHK:799)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: IGG Inc, an investment holding company with a market cap of HK$5.19 billion, develops and operates mobile and online games across Asia, North America, Europe, and other international markets.
Operations: The company generates revenue of HK$5.72 billion from its development and operation of online games.
Market Cap: HK$5.19B
IGG Inc operates with a strong financial foundation, being debt-free and having short-term assets of HK$3 billion that exceed both its short and long-term liabilities. The company has experienced a decline in earnings over the past five years, with recent negative growth making it challenging to compare against industry averages. Despite this, IGG's Price-To-Earnings ratio of 9.1x suggests it's trading at good value relative to peers. The board's average tenure is 9.3 years, indicating seasoned leadership. Recent announcements include a special dividend alongside an interim dividend decrease for H1 2025, reflecting an unstable dividend history amidst stable earnings quality.
- Navigate through the intricacies of IGG with our comprehensive balance sheet health report here.
- Review our growth performance report to gain insights into IGG's future.
Kintor Pharmaceutical (SEHK:9939)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Kintor Pharmaceutical Limited is a clinical-stage company in China that develops small molecules and biologic drugs for dermatology and oncology, with a market cap of HK$1.23 billion.
Operations: Kintor Pharmaceutical Limited has not reported any revenue segments.
Market Cap: HK$1.23B
Kintor Pharmaceutical, a clinical-stage biotech firm in China, is pre-revenue with limited sales (CN¥11 million) and a net loss of CN¥83.27 million for H1 2025. Recent developments include the completion of subject enrollment for KT-939's long-term safety trial, targeting melanin production with promising safety and efficacy results. The company also completed a follow-on equity offering of HK$42.99 million to bolster its financial position amid high volatility and short cash runway concerns. Despite unprofitability, Kintor is advancing several innovative dermatology treatments through clinical trials, potentially enhancing its market position if successful approvals are obtained.
- Jump into the full analysis health report here for a deeper understanding of Kintor Pharmaceutical.
- Learn about Kintor Pharmaceutical's historical performance here.
Make It Happen
- Click this link to deep-dive into the 977 companies within our Asian Penny Stocks screener.
- Searching for a Fresh Perspective? These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Kintor Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com